Ryan C. Widau

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Roy S. Herbst, Hendrik‐Tobias Arkenau, Rafael Santana-Dávila et al. · The Lancet Oncology · 2019 · 271 citations · Full text

Urothelial Carcinomas, Medicine, Clinical Trials +9

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 175 citations · Full text

Platinum-based Therapy, Urology, Metastatic Urothelial Carcinoma +8

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)

Hendrik‐Tobias Arkenau, Juan Martín-Liberal, Emiliano Calvo et al. · The Oncologist · 2018 · 166 citations · Full text

STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability

Diana Rose E. Rañoa, Ryan C. Widau, Stephen Mallon et al. · Cancer Research · 2018 · 95 citations · Full text

RIG-I–like receptor LGP2 protects tumor cells from ionizing radiation

Ryan C. Widau, Akash D. Parekh, M.C. Ranck et al. · Proceedings of the National Academy of Sciences · 2014 · 88 citations · Full text